Cargando…
New insights for drug resistance in metastatic castration-resistant prostate cancer
Prostate cancer is the most common cancer and is the second leading cause of cancer-related deaths among men in the United States. Androgen deprivation therapy (ADT) is the standard treatment for advanced-stage prostate cancer; however, this treatment eventually fails, leading to an incurable diseas...
Autores principales: | Kushwaha, Prem Prakash, Gupta, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511793/ https://www.ncbi.nlm.nih.gov/pubmed/36176749 http://dx.doi.org/10.20517/cdr.2022.83 |
Ejemplares similares
-
Emerging targets in cancer drug resistance
por: Kumar, Shashank, et al.
Publicado: (2019) -
The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
por: De Santis, Maria, et al.
Publicado: (2019) -
New immunotherapeutic paradigms for castration-resistant prostate cancer
por: Galluzzi, Lorenzo
Publicado: (2013) -
New ideas in preventing castration-resistant prostate cancer
por: Tsai, Yuan-Chin, et al.
Publicado: (2017) -
Insights into the prognostic potential of total alkaline phosphatase
in metastatic castration-resistant prostate cancer treated with
radium-223
por: Viani, Gustavo
Publicado: (2023)